Hickey David
Known title: EVP & President, Life SciencesCIK: 0001838891
Associated companies
Transaction History
| BDX | ▲ Buy | Grant | 1,663 | $0 | 11/26/2023 | View on chart |
| BDX | ▲ Buy | Option Exercise | 3,883 | $515K | 8/11/2023 | View on chart |
| BDX | ▼ Sell | Other | 1,857 | $516K | 8/11/2023 | View on chart |
| BDX | ▼ Sell | Open Market | 2,974 | $826K | 8/11/2023 | View on chart |
| BDX | ▲ Buy | Grant | 1,816 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 475 | $126K | 8/15/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 475 | $122K | 5/6/2022 | View on chart |
| BDX | ▲ Buy | Grant | 1,473 | $0 | 11/26/2021 | View on chart |
| BDX | ▼ Sell | Open Market | 500 | $130K | 9/8/2021 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 268 | $0 | 9/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.